Why is "Actinium" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-10 07:59:09
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Actinium is a chemical element; it has symbol Ac and atomic number 89. It was discovered by Friedrich Oskar Giesel in 1902, who gave it the name emanium; the element got its name by being wrongly identified with a substance André-Louis Debierne found in 1899 and called actinium. The actinide series, a set of 15 elements between actinium and lawrencium in the periodic table, is named after actinium. Together with polonium, radium, and radon, actinium was one of the first non-primordial radioactive elements to be discovered.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting - PR Newswire
-
Expanded Actinium‑225 Capacity And Higher EPS Guidance Could Be A Game Changer For Cardinal Health (CAH) - Yahoo Finance
-
ATNM Stock Price, Quote & Chart | ACTINIUM PHARMACEUTICALS INC (NYSEARCA:ATNM) - ChartMill
-
How Investors Are Reacting To Cardinal Health (CAH) Expanding Actinium-225 Capacity For Targeted Alpha Therapies - simplywall.st
-
Actinium-225 Demonstrates Safety and Responses in mCRPC - Targeted Oncology
-
Actinium Pharma unveils groundbreaking data on radiotherapy platform at AACR 2026 - Indian Pharma Post
-
Pennsylvania to house new actinium-225 manufacturing facility - European Pharmaceutical Review
-
Radiopharma Sector Races To Secure Actinium-225 Supply as Pipelines Expand - BioSpace
-
Laser spectroscopy and CP-violation sensitivity of actinium monofluoride - Nature
-
Cardinal Health expands Actinium-225 production capacity to support growing demand for novel cancer therapies - PR Newswire
-
Promising Phase 1 Data for Actinium-225 Presented at 2026 ASCO GU - Targeted Oncology
-
A Look At Cardinal Health (CAH) Valuation After Expanded Actinium-225 Cancer Therapy Production - Sahm
-
Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeut - PR Newswire
-
Exploring the Role of Actinium-225 in Metastatic Castration-Resistant Prostate Cancer - Targeted Oncology
-
Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposiu - PR Newswire
-
Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat - PR Newswire
-
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Br - PR Newswire
-
Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Confer - PR Newswire
-
Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat - PR Newswire
-
Cardinal Health Deepens Actinium-225 Role As Board Leadership Shifts - Yahoo Finance
-
Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference - PR Newswire
-
Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications - PR Newswire
-
Actinium to present preclinical data at AACR meeting April 21 - Investing.com
-
TerraPower Commits $450M To Build Radioisotope Production Plant - BioSpace
-
TerraPower Isotopes Invests $450M in Actinium-225 Production Facility - Oncodaily
-
Actinium: Q4 Earnings Snapshot - 10TV
-
AstraZeneca locks in long-term actinium-225 supply with Niowave - The Pharma Letter
-
Actinium Pharmaceuticals (ATNM) board adopts annual Say-on-Pay advisory votes - Stock Titan
-
Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? - Yahoo Finance
-
Cancer drug developers get more Actinium-225 as Cardinal Health expands - Stock Titan
-
Jeri Kim: Thrilled to Join Actinium Pharmaceuticals as VP, Head of Solid Tumor Clinical Development - Oncodaily
-
The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet - TMX Newsfile
-
Phase 1 Trial of an Actinium-Labeled KLK2-Targeting Antibody for mCRPC - Michael Morris - UroToday
-
Novartis prunes its pipeline | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
-
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficac - PR Newswire
-
ASCO 2025: PSMA-Targeted Actinium-225 Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Baseline and Follow-up PSMA PET Parameters Associated with Outcomes - UroToday
-
UCLA Health launches novel clinical trial for recurrent prostate cancer - UCLA Health
-
Belgium’s PanTera Begins Construction Of Dedicated Actinium-225 Facility - NucNet
-
Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medic - PR Newswire
-
Why Is Actinium Pharmaceuticals Stock Rising Today? - Stocktwits
-
Niowave and Novartis Enter Global Actinium-225 Supply Agreement to Advance Next-Generation Cancer Therapies - Yahoo Finance
-
Niowave Expands Global Supply Agreement with AstraZeneca to Deliver Actinium-225 for Next-Generation Cancer Therapies - PR Newswire
-
BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research - BioSpace
-
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting - Morningstar
-
High-energy resolution X-ray spectroscopy reveals bonding characteristics of La - Nature
-
Actinium 2025 10-K: $0.09M revenue and $(1.09) EPS on $(33.887)M net loss - TradingView — Track All Markets
-
Cardinal Health expands Actinium-225 production capacity to support growing demand for novel cancer therapies - WFXG
-
SK biopharmaceuticals secures European supply of actinium-225 through deal with Germany's Eckert & Ziegler - koreabiomed.com
-
Cardinal Health’s Actinium-225 Expansion: Is the Premium Already Paying for Future Success? - Bitget
-
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
-
If You Invested $1,000 in Actinium Pharmac (ATNM) - Stock Titan
-
Actinium-PSMA J591 After Prior Lutetium Therapy in Metastatic Prostate Cancer - Scott Tagawa - UroToday
-
Novartis Actinium 225 Deal Supports Radioligand Focus And Valuation Case - Yahoo Finance
-
Comparing Lead-212 and Actinium-225 Alpha Emitters for Prostate Cancer Treatment "Presentation" - Alfred Morgenstern - UroToday
-
Cardinal Health (CAH) Boosts Actinium-225 Production for Future Therapies - GuruFocus
-
New NIST Standard Helps Deliver the Right Dosage of Cancer-Fighting Drugs - National Institute of Standards and Technology (.gov)
-
Cardinal Health expands Actinium-225 production capacity to supp - GuruFocus
-
Mayo Clinic treats first person in the US with a novel radiopharmaceutical therapy for breast cancer - Mayo Clinic News Network
-
Cardinal Health (CAH) Boosts Actinium-225 Production Capacity - GuruFocus
-
AtomVie Global Radiopharma and TerraPower Isotopes Announce Strategic Supply Agreement for Actinium-225 to Advance Radiopharmaceutical Development and Manufacturing - PR Newswire
-
Ratio Therapeutics and TerraPower Isotopes Sign Supply Agreement for Actinium-225 For Targeted Radiotherapeutics - PR Newswire
-
Niowave And Novartis Enter Global Actinium-225 Supply Agreement To Advance Next-Generation Cancer Therapies - TradingView — Track All Markets
-
Niowave to supply actinium-225 to Novartis under long-term agreement - DOTmed
-
Safety and Activity of Alpha-Emitting Ac-225-PSMA-617 Radioligand Therapy in mCRPC That Has Progressed After Lu-177-PSMA, Journal Club – Christopher Wallis & Zachary Klaassen - UroToday
-
Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center - PR Newswire
-
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Rese - PR Newswire
-
Actinium’s ATNM-400 demonstrates superior efficacy in prostate cancer - BioWorld News
-
Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting - PR Newswire
-
How Eckert & Ziegler’s Actinium-225 Radio-DARPin Partnership (XTRA:EUZ) Has Changed Its Investment Story - simplywall.st
-
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact Levi & Korsinsky - PR Newswire
-
Bayer initiates Phase I study targeting GPC3 with actinium-225 radiopharmaceutical in patients with advanced hepatocellular carcinoma - Bayer
-
Actinium-225 illustration with cancer cell and alpha radiation - National Institute of Standards and Technology (.gov)
-
Ratio, Ionetix ink separate deals to speed production of in-demand radiopharmaceutical isotopes - Fierce Pharma
-
BMS's RayzeBio unit opens $160M radiopharma plant in Indianapolis - FirstWord Pharma
-
Clinical Experience with Actinium-PSMA Across Multiple Treatment Centers "Presentation" - Alfred Morgenstern - UroToday
-
Promising Data Presented on Novel Radiotherapy for AML, MDS, Myeloid Malignancies - Docwire News
-
IONETIX Corporation and AlfaRim Medical B.V. announce a strategic partnership to fast-track commercial production of Actinium-225 - PR Newswire
-
Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives - PR Newswire
-
Patented technology removes key radioactive contaminant in critical minerals processing - ANSTO
-
Actinium chelation and crystallization in a macromolecular scaffold - Nature
-
Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities - PR Newswire
-
Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today - PR Newswire
-
ACCEL Trial Tests Actinium-225-PSMA-62 in Prostate Cancer - Ramy Saleh - UroToday
-
Bayer Initiates Phase I Study Targeting GPC3 With Actinium-225 Radiopharmaceutical in Patients With Advanced Hepatocellular Carcinoma - BioSpace
-
Is Actinium Really Happening? - Journal of Nuclear Medicine
-
TerraPower Isotopes Brings Actinium-225 to Market - TerraPower
-
Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225 - PR Newswire
-
Novartis goes earlier with actinium | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
-
From warhead to cancer-killer, the quest for more actinium-225 - Drug Discovery News
-
Caught in the Actinium - Berkeley Lab News Center (.gov)
-
Actinium Shareholder Sues Leaders Over Cancer Therapy FDA Delay - Bloomberg Law News
-
Hong Kong to host Asia’s first Actinium-225 isotope plant for cancer therapy - The Standard (HK)
-
Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO® - PR Newswire
-
Actinium Pharmaceuticals 2026 Annual Report: Clinical-Stage Radiopharmaceutical Innovations, Competitive Strengths, and Regulatory Risk Factors - Minichart
-
Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration - PR Newswire
-
Exploring Actinium-225 in PSMA-Targeted Therapy for Prostate Cancer - Michael Morris - UroToday
-
Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia - PR Newswire
-
Actinium-225 shows clinical activity in metastatic castration-resistant prostate cancer - ESMO Daily Reporter
-
Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML - PR Newswire
-
FDA sinks Actinium's radiotherapy blood cancer filing plans, prompting pivot to partnering - Fierce Biotech
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.